Eledon Pharmaceuticals In... (ELDN)
Eledon Pharmaceuticals Statistics
Share Statistics
Eledon Pharmaceuticals has 59.88M shares outstanding. The number of shares has increased by 55.51% in one year.
| Shares Outstanding | 59.88M |
| Shares Change (YoY) | 55.51% |
| Shares Change (QoQ) | 0.24% |
| Owned by Institutions (%) | 74.08% |
| Shares Floating | 54.72M |
| Failed to Deliver (FTD) Shares | 76.32K |
| FTD / Avg. Volume | 31.94% |
Short Selling Information
The latest short interest is 1.46M, so 2.44% of the outstanding shares have been sold short.
| Short Interest | 1.46M |
| Short % of Shares Out | 2.44% |
| Short % of Float | 2.73% |
| Short Ratio (days to cover) | 5.32 |
Valuation Ratios
The PE ratio is -5.66 and the forward PE ratio is -3.18. Eledon Pharmaceuticals's PEG ratio is 0.
| PE Ratio | -5.66 |
| Forward PE | -3.18 |
| PS Ratio | 0 |
| Forward PS | 3.7 |
| PB Ratio | 1.69 |
| P/FCF Ratio | -4.23 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Eledon Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.42, with a Debt / Equity ratio of 0.01.
| Current Ratio | 12.42 |
| Quick Ratio | 12.42 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | - |
| Debt / FCF | -0.02 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1.14M |
| Employee Count | 31 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -431K |
| Effective Tax Rate | 1.21% |
Stock Price Statistics
The stock price has increased by 70.56% in the last 52 weeks. The beta is 0.67, so Eledon Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 0.67 |
| 52-Week Price Change | 70.56% |
| 50-Day Moving Average | 3.62 |
| 200-Day Moving Average | 3.55 |
| Relative Strength Index (RSI) | 53.91 |
| Average Volume (20 Days) | 238.91K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | 0 |
| Net Income | -35.32M |
| EBITDA | 0 |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.73 |
Balance Sheet
The company has 20.55M in cash and 954K in debt, giving a net cash position of 19.59M.
| Cash & Cash Equivalents | 20.55M |
| Total Debt | 954K |
| Net Cash | 19.59M |
| Retained Earnings | -355.59M |
| Total Assets | 177.41M |
| Working Capital | 132.15M |
Cash Flow
In the last 12 months, operating cash flow was -47.27M and capital expenditures 0, giving a free cash flow of -47.27M.
| Operating Cash Flow | -47.27M |
| Capital Expenditures | 0 |
| Free Cash Flow | -47.27M |
| FCF Per Share | -0.97 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ELDN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for ELDN is $16, which is 376.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $16 |
| Price Target Difference | 376.2% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Oct 5, 2020. It was a backward split with a ratio of 1:18.
| Last Split Date | Oct 5, 2020 |
| Split Type | backward |
| Split Ratio | 1:18 |
Scores
| Altman Z-Score | -1.42 |
| Piotroski F-Score | 1 |